Evotec SE (Nasdaq:EVO) announced that it will work with Janssen Pharmaceutica NV, a subsidiary of the Janssen Pharmaceutical Companies (NYSE:JNJ), to identify drug targets and to partner on hit identification and lead optimization of chemical assets. The partnership will center around Evotec’s end-to-end drug discovery and development platform. “We are very proud to enter into…